

- and coronary disease incidence rates
67:54; 68:27
- and coronary disease, in women
74:9, 10
- and coronary disease mortality
67:10, 26-67
- in coronary disease patients
67:26, 28
- in coronary disease patients, effect on blood pressure
67:61
- in coronary disease patients, effect on heart function
67:61
- in coronary disease patients, effect on heart rate
67:61
- and coronary thrombosis mortality for men
67:26
- and diet
67:66
- and digestive tract neoplasms mortality
67:30
- duration of,
64:29, 31, 37, 187, 188
- duration of, and lung neoplasm increase
64:31, 37, 158, 161, 163, 170, 187, 188
- duration of habit and incidence of CHD
68:17
- effect of abstinence in exercise performance
73:241, 242, 246, 247
- effect on bladder neoplasm morbidity
67:155
- effect on blood cholesterol levels
67:55, 56
- effect on blood circulation
67:26, 60-61; 69:11
- effect on blood circulation, and arteriosclerosis pathogenesis
67:61-62
- effect on blood circulation, and coronary disease pathogenesis
67:62
- effect on blood coagulation
67:64
- effect on blood lipids
68:31; 73:11, 12
- effect on blood platelets
67:64; 69:27-28; 74:18, 19
- effect on blood pressure
67:54, 60
- effect on blood vessels
67:111
- effect on bronchial epithelium
67:104-106, 144
- effect on cardiac lactate metabolism
73:13
- effect on cardiovascular system
67:26, 60; 72:6, 13, 14
- effect on coronary vessels
67:65
- effect on esophageal sphincter
72:97, 98
- effect on esophageal tissue
67:30, 150-153
- effect on free fatty acids
69:27
- effect on gastric acidity
67:182
- effect on gastrointestinal secretions in dogs
72:6
- effect on heart function
67:60
- effect on heart rate
67:60
- effect on hemoglobin oxygen affinity
69:29
- effect on larynx and true vocal cords
69:59-60
- effect on leg blood mean-flow capacity
73:22
- effect on leukocytes in guinea pigs
72:46
- effect on lung function
67:29, 55; 69:5
- effect on lungs
67:104, 140-143
- effect on lungs in dogs
72:46
- effect on mortality rates from esophageal neoplasms in Japanese males
72:71
- effect on mucous membranes
67:144
- effect on myocardium
67:60
- effect on neoplasm recurrence at site of primary
72:69
- effect on oxygen tension in arterial blood
72:45
- effect on pentagastrin-stimulated gastric secretion
72:97
- effect on peripheral circulatory system
72:25, 26
- effect on plasma nicotine levels
73:15-17
- effect on precapillary sphincters
73:22
- effect on pulmonary clearance
72:47
- effect on respiratory tract
67:141
- effect on thrombus formation
69:27-28
- effect on thrombus formation in coronary disease patients
67:26
- effect on tryptophan metabolism
67:36, 156
- effect on vascular resistance
67:60
- effect on ventilation/perfusion relationships of lung
69:39
- effect on vision
67:183
- electrocardiogram patterns from
64:319

- and emphysema morbidity
 - 67:3, 6, 94, 99
- and emphysema mortality
 - 67:3, 29, 90-92
- in emphysema pathogenesis
 - 67:29-31, 96, 104, 106; 69:37-38
- and epidermoid carcinoma
 - 67:35, 140-143
- and esophageal neoplasms
 - 67:33, 149, 150-151
- and fertility history
 - 69:79-80
- genetic factors in
 - 64:190, 385
- and gingivitis
 - 69:85-86
- health hazards of, similarities of cigarettes with little cigars
 - 73:224, 225
- heartburn and
 - 72:97, 98
- histopathologic changes from
 - 64:300
- inhalation of cigarette smoke as measure of exposure to
 - 67:15
- interaction with other risk factors in CHD
 - 73:4-11
- and intermittent claudication
 - 74:14-16
- and kidney neoplasms
 - 69:60
- in laryngeal neoplasm etiology
 - 67:3, 148; 69:55
- in laryngeal neoplasm etiology in men
 - 67:33
- and liver cirrhosis morbidity
 - 67:39
- and liver cirrhosis mortality
 - 67:10, 36
- and lung neoplasms
 - 64:175-196; 69:4, 55-58
- and lung neoplasms etiology
 - 67:33-34, 140-144
- and lung neoplasms incidence
 - 68:94-99
- and lung neoplasms, in men
 - 69:57
- and lung neoplasms, in women
 - 67:10; 69:67
- and lung neoplasms morbidity
 - 67:3, 142
- and lung neoplasms mortality
 - 67:3, 10, 34
- and lung neoplasms, retrospective studies of, by smoking characteristics
 - 64:156
- as a major risk factor in peripheral vascular disease
 - 74:14-16
- and morbidity by age
 - 67:24
- and morbidity in United States
 - 67:6, 19
- and mortality
 - 69:3
- and mortality, British men
 - 67:10
- and mortality, British physicians
 - 67:5
- mortality, follow-up study
 - 67:8
- mortality from esophageal neoplasms
 - 68:102
- and mortality in United States
 - 67:5
- and mortality rates by sex
 - 67:7
- and mortality, U.S. veterans
 - 67:5
- and mouth neoplasms
 - 67:145
- and myocardial infarction
 - 69:4, 18
- and myocardial infarction incidence rates
 - 67:57
- and noncancerous oral diseases
 - 69:5-6, 85-87
- and oat cell carcinoma
 - 67:140-141
- and obesity
 - 67:66
- and oral neoplasms
 - 69:58
- and oral neoplasms incidence
 - 68:99, 100
- and pancreatic neoplasms
 - 67:36, 159; 69:60-61
- patterns
 - 64:368, 369
- and peptic ulcer
 - 67:39; 72:6, 97, 98
- and peptic ulcer morbidity
 - 67:39-40, 181-182
- and peptic ulcer mortality
 - 67:39-40, 180-182
- pleasure
 - 64:350
- population studies
 - 67:8-11
- and premalignant changes in larynx
 - 69:5
- prevalence of
 - 64:363, 364
- prevalence of, in nonwhites
 - 64:363, 364
- prevalence of in U.S. and Great Britain
 - 73:173, 174
- psychoanalytic explanation of
 - 64:367
- and pulmonary fibrosis
 - 67:107; 72:44
- rate
 - 64:98
- reduction of among British physicians, and reduced mortality
 - 67:15
- reduction of, effect on lung neoplasm mortality
 - 67:4
- relation to blood cholesterol and lung neoplasms
 - 69:57

- relation to lung neoplasms and stomach
ulcers
69:57
- and respiratory tract infections
67:10
- and restricted activity
67:19
- status, errors of measurement in
64:111
- and stomach neoplasms
67:29, 36, 158
- and stroke
67:27
- and thrombosis
67:111
- tobacco amblyopia and
72:6
- trends for U.S. men, for years 1955,
1966, and 1970
74:40
- and tryptophan metabolites in urine
67:36
- type, esophageal neoplasms and
64:32, 33
- type, mortality ratios by
64:90
- type, neoplasm sites by
64:188
- type, oral neoplasm sites by
64:197
- type, retrospective neoplasm studies
64:201
- typology
67:189-191
- and undifferentiated carcinoma
67:140-143
- vasoconstrictive effects in normal sub-
jects
74:16
- wish- for-adult-status as reason for
64:371
- withdrawal methods and
64:352
- in young people, effect on lung function
67:110
- in young people, effect on respiratory
tract
67:31
- See also* Reverse smoking; Passive smok-
ing; Smoking, bidi; Smoking, cigar;
Smoking, pipe
- Smoking, bidi
64:211
- esophageal neoplasms from
64:213
- in neoplasm etiology in Bombay, India
72:69
- Smoking characteristics
bronchitis prevalence rates in men and
74:79
- COPD prevalence rates in Yugoslavia and
74:79
- dosage score and
67:14-15
- and incidence rates of lung neoplasms
for men
69:56
- and incidence rates of lung neoplasms
for women
69:56
- and lung neoplasm mortality rates
69:57
- lung neoplasm mortality rates, for men
by
67:134-135, 139
- lung neoplasm mortality rates, for
women by
67:136
- lung neoplasm mortality ratios, for men
by
67:139
- lung neoplasm mortality ratios, for
women by
67:136
- patients with lung or bladder neoplasms
68:104
- Smoking, cigar
autopsy studies, in smokers with emphy-
sema, fibrosis, or thickening of arte-
rioles or arteries
75:75
- and bronchitis morbidity
67:94, 99
- and bronchitis mortality
67:30, 94
- CO levels in mainstream smoke
75:90
- effect on blood lipids
68:31
- effect on mortality and morbidity com-
pared to cigarette smoking
73:171-173
- and emphysema morbidity
67:94
- and emphysema mortality
67:30, 94
- in esophageal neoplasm development
73:197, 200-202
- gastrointestinal disorders and
73:222
- health consequences of
73:179
- histological effects on bronchial epithe-
lium
73:203, 204, 209
- histological effects on esophagus
73:200
- histological effects on larynx
73:197
- histological effects on lungs
73:217
- incidence of CHD
68:27
- incidence of lung neoplasms in Switzer-
land
68:95, 96
- inhalation patterns and
73:184-189
- in laryngeal neoplasm development
73:197-199
- in lung neoplasm development
73:203-206; 74:39, 40
- and lung neoplasm mortality
67:34, 138-140

- and lung neoplasm mortality ratios
 - 67:138-140; 73:203-205
- and mortality
 - 67:7
- mortality from esophageal neoplasms
 - 68:102
- mortality, in smokers vs. nonsmokers
 - 68:5
- mortality ratios from cardiovascular diseases and
 - 73:215, 216
- mortality ratios from COPD and
 - 73:217, 219
- mortality ratios from esophageal neoplasms and
 - 73:197, 200
- mortality ratios from laryngeal neoplasms and
 - 73:193, 196, 197
- mortality ratios from oral neoplasms and
 - 73:191, 193
- oral neoplasm development and
 - 73:193-195
- overall mortality rates by amount smoked
 - 73:180-182
- overall mortality rates from neoplasms
 - 73:189
- prevalence in Great Britain
 - 73:173, 174
- prevalence in United States
 - 73:173, 174
- relationship to neoplasms
 - 75:43, 44
- summary of previous findings on effects
 - 75:4, 13
- and tobacco amblyopia
 - 67:39
- see also* Smoking
- Smoking classification
 - bladder neoplasms mortality rates by
 - 67:155
 - bronchitis mortality by
 - 67:30
 - bronchitis respiratory symptoms by
 - 67:98
 - cerebrovascular disease mortality rates by age and sex
 - 67:66
 - cerebrovascular disease mortality ratios by age and sex
 - 67:66
 - cough by
 - 67:97
 - digestive tract mortality rates by
 - 67:147
 - emphysema mortality by
 - 67:30
 - esophageal neoplasms mortality rates by
 - 67:50
 - esophageal neoplasms mortality ratios by
 - 67:150
 - laryngeal neoplasms mortality rates by
 - 67:147-149
 - laryngeal neoplasms mortality ratios by
 - 67:149
 - liver cirrhosis mortality rates in men
 - 67:184
 - liver cirrhosis mortality ratios for men
 - 67:184
 - lung neoplasms morbidity by
 - 67:33, 143
 - lung neoplasms mortality rates by
 - 67:34, 137, 139-140, 143
 - lung neoplasms mortality ratios by
 - 67:137, 139-140
 - mortality rates by
 - 67:8
 - mouth neoplasm morbidity by
 - 67:32
 - mouth neoplasm mortality by
 - 67:35, 146
 - pancreatic neoplasms mortality rates for men by
 - 67:159
 - pancreatic neoplasms mortality rates for U.S. veterans by
 - 67:159
 - pancreatic neoplasms mortality ratios for men by
 - 67:159
 - peptic ulcer mortality rates for men by
 - 67:182
 - pharyngeal neoplasms mortality by
 - 67:35, 146
 - respiratory tract neoplasms mortality rates by
 - 67:147
 - stomach neoplasms mortality rates by
 - 67:157-158
 - stomach neoplasms mortality ratios by
 - 67:157
 - tracheal neoplasms mortality rates by
 - 67:147
 - urinary tract neoplasms mortality rates by
 - 67:154
 - urinary tract neoplasms mortality ratios by
 - 67:154
- Smoking habit
 - 64:366
 - appetite reduction by
 - 64:71, 355
 - behavioral research
 - 67:188-192
 - beneficial effects of
 - 64:32, 355
 - and body constitution
 - 67:54
 - British physicians
 - 67:9-10
 - and cognition
 - 67:189-191
 - compulsive nature of
 - 64:352
 - and cultural characteristics
 - 67:54
 - demographic factors in
 - 64:361-365
 - and heredity
 - 67:53-54
 - intelligence factors in
 - 64:370
 - measurement of
 - 64:98

- modification of
 - 64:375, 376
- mortality rates associated with
 - 64:27
- nausea from
 - 64:71
- neuroticism and
 - 64:367
- and occupational physical activity
 - 67:56
- oral hypothesis of
 - 64:367, 363
- and perception
 - 67:189-191
- and personality characteristics
 - 67:57
- psychological determinants in
 - 64:40, 350
- psychosocial aspects of
 - 67:39, 188-192
- reasons for
 - 67:189
- and religion
 - 67:54
- social determinants in
 - 64:361-374
- and socioeconomic
 - 67:54
- see also* Tobacco habit
- Smoking history**
 - aortic aneurysm mortality rates by
 - 69:16
 - aortic aneurysm mortality ratios by
 - 69:16
 - and bronchitis prevalence rates
 - 67:96
 - and chronic diseases
 - 67:22
 - and coronary disease incidence rates
 - 69:21-24
 - and coronary disease mortality rates
 - 67:25-26; 69:13-14, 17
 - and coronary disease mortality rates, for ex-smokers
 - 67:51
 - coronary disease mortality ratios
 - 69:13, 15, 18
 - incidence of atypical nuclei in larynx by
 - 69:59
 - and laryngeal neoplasms
 - 67:35
 - and lung neoplasm morbidity
 - 67:33
 - and lung neoplasm mortality rates
 - 67:34, 135-137, 139-140
 - and lung neoplasm mortality rates for ex-smokers
 - 67:137, 139
 - and mortality
 - 67:7-9
 - and respiratory disease morbidity
 - 67:98
 - and respiratory function tests
 - 67:100
 - and stroke
 - 67:68
 - and stroke mortality rates
 - 69:13, 17
 - and stroke mortality ratios
 - 69:13, 15
- Smoking machines**
 - 64:45
- Smoking, maternal**
 - and abortion
 - 69:77-79; 71:13; 72:5, 84, 85; 73:123, 124
 - carboxyhemoglobin levels
 - 69:80
 - carcinogenic effects on fetus
 - 72:88
 - congenital malformations and
 - 73:136, 137
 - and development of bronchitis and pneumonia in infants
 - 75:103, 104
 - effect during pregnancy
 - 67:185-186; 72:5, 83-87; 73:103-142
 - effect on birth weight
 - 67:39-40, 185; 69:5, 77-78, 80; 72:5, 83-87; 73:103-114, 119-122
 - effect on body height of children
 - 72:88
 - effect on fetal growth rate
 - 72:5, 83-87
 - effect on fetal morbidity
 - 67:186
 - effect on fetal mortality
 - 67:185; 69:77-78; 73:124, 125
 - effect on gestation duration
 - 73:103-106
 - effect on infant mortality
 - 67:185; 69:77-78; 72:84-87
 - effect on infants growth rate
 - 69:78
 - effect on lactation
 - 73:138-141
 - effect on neonatal carboxyhemoglobin levels
 - 73:118, 119
 - effect on neonate
 - 67:39-40, 185
 - effect on neoplasm development in offspring
 - 72:87, 88
 - effect on placental ability to hydroxylate benzo(a)pyrene
 - 69:80
 - effect on placental metabolizing activity
 - 72:89
 - effect on pregnancy
 - 69:4-5, 77-81
 - effect on pregnancy, in Ireland
 - 69:79
 - effect on pregnancy, in Scotland
 - 69:79
 - effect on pregnancy, in Venezuela
 - 69:79
 - effect on sex ratio
 - 73:135, 136
 - epidemiological studies of effects
 - 69:77-80
 - preeclampsia and
 - 69:79; 72:84; 73:142
 - pregnancy toxemias and
 - 69:79
 - and prematurity
 - 67:185; 69:77, 79

- and prematurity, among Negroes
 - 69:78
- selective action on fetus of certain women vs. others
 - 73:131
- teratogenic effects
 - 77:87
- timing of influence on birth weight
 - 73:120, 121
- unwanted pregnancy and
 - 72:84
- see also* Infant mortality; Neonates
- Smoking, parental
 - effect on children
 - 72:129
- Smoking, paternal
 - effect on infant birth weight
 - 73:110, 111
- Smoking, pipe
 - and adenocarcinoma
 - 67:143
 - autopsy studies, in smokers with emphysema, fibrosis, or thickening of arterioles or arteries
 - 75:75
 - and bronchitis morbidity
 - 67:94, 99
 - and bronchitis mortality
 - 67:94, 99
 - effect on mortality and morbidity compared to cigarette smoking
 - 73:171-173
 - and emphysema morbidity
 - 67:94
 - and emphysema mortality
 - 67:34
 - and epidermoid carcinoma
 - 67:143
 - in esophageal neoplasm development
 - 73:197, 200-202
 - gastrointestinal disorders and
 - 73:222
 - health consequences of
 - 73:179
 - histological effects on bronchial epithelium
 - 73:203, 204, 209
 - histological effects on esophagus
 - 73:200
 - histological effects on larynx
 - 73:197
 - inhalation patterns and
 - 73:184-189
 - in laryngeal neoplasm development
 - 73:197-199
 - and lip neoplasms
 - 67:35, 145
 - in lung neoplasm etiology
 - 67:143; 74:39, 40
 - in lung neoplasm etiology by amount smoked
 - 73:203-206
 - and lung neoplasm mortality
 - 67:34, 139-140
 - and lung neoplasm mortality ratios
 - 67:139-140; 73:203-205
 - and mortality
 - 67:7
 - and mortality ratios
 - 64:86, 87
 - mortality ratios from cardiovascular diseases and
 - 73:215, 216
 - mortality ratios from COPD and
 - 73:217, 219
 - mortality ratios from laryngeal neoplasms and
 - 73:193, 196, 197, 200
 - mortality ratios from oral neoplasms
 - 73:191, 193
 - and mouth neoplasms
 - 67:33
 - oral neoplasms development and
 - 73:193-195
 - overall mortality rates by amount smoked
 - 73:180-182
 - overall mortality rates from neoplasms and
 - 73:189
 - prevalence in Great Britain
 - 73:173, 174
 - prevalence in United States
 - 73:173, 174
 - pulmonary histological changes and
 - 73:217
 - relationship to cancer
 - 75:43, 44
 - sedation from
 - 64:350
 - stomatitis nicotina from
 - 64:271; 69:87
 - summary of previous findings on effects on smokers
 - 75:4, 13
 - and tobacco amblyopia
 - 67:39
 - see also* Smoking
- Snuff
 - 64:73, 349
 - effect on oral mucosa in hamsters
 - 72:70
 - lip neoplasms from
 - 64:202
 - oral lesions from
 - 64:203
 - oral neoplasms
 - 64:202, 233; 71:287, 361, 364-365
 - per capita consumption of, in U.S.
 - 64:45
- Social adjustments
 - in children of smoking mothers
 - 71:407
- Social stimulation
 - 64:32
- Socioeconomic level
 - smoking prevalence by
 - 64:362
- Socioeconomics
 - in COPD
 - 71:152-153, 216-217
 - and smoking habit
 - 67:54
- Sodium
 - in main stream smoke
 - 64:55

- Solanesol
 - 64:52
 - pyrolysis of
 - 64:53
 - structural formula of
 - 64:53
- Somatotypes
 - 64:372, 383, 384, 385, 386
- Soot
 - benzo(a)pyrene content of
 - 64:148
 - neoplasm induction by
 - 64:33, 147, 229
- South Africa
 - coronary death rate in
 - 64:320
 - esophageal neoplasms in, retrospective studies of tobacco use
 - 71:378
 - health surveys in
 - 64:186
 - methods of retrospective studies of lung neoplasms in
 - 71:328
 - occupational exposure and smoking relationship to COPD in
 - 71:219
 - serum lipid differences in smokers vs. nonsmokers in
 - 71:99
- Specificity
 - as measure of statistical association
 - 64:182-185, 204, 210, 225
- Spirometric test
 - 64:292
- Sports
 - smokers' participation in
 - 64:372, 373
- Spray exposure
 - in smokers vs. nonsmokers, by race and sex
 - 75:69, 70
- Sputum
 - 64:38, 282, 283-287, 301
 - effect of asbestos exposure in smokers vs. nonsmokers
 - 73:41
 - effect of filtered cigarettes
 - 73:55
 - effect of modified cigarettes
 - 73:37, 38
 - effect of plain vs. filtered cigarettes
 - 73:37, 38
 - in males by amount smoked and type of cigarette
 - 73:37, 38
 - prevalence in pipe and cigar smokers
 - 73:220, 221
 - in women
 - 64:231
- Squalene
 - 64:51
- Status striving
 - smoking and
 - 64:372, 373
- Stearic acid
 - suspected carcinogenic agent of cigarette smoke
 - 71:266
- Steel workers
 - 64:285, 299
- Sterols
 - 64:52
- Stigmasterol
 - 64:52
 - pyrolysis of
 - 64:59
- Stillbirths
 - abortions, and neonatal death and, in smoking and non-smoking mothers
 - 71:390, 405-406
 - effects of maternal smoking
 - 71:415; 73:124, 125
 - rates in blacks vs. whites
 - 73:124, 125
 - in smokers vs. nonsmokers
 - 73:124, 125
 - see also* Fetal death; Smoking, maternal
- Stimulants
 - 64:354
 - nicotine as
 - 64:38, 69, 70, 71, 317-320, 349-350
- Stockholm Prospective Study
 - epidemiologic study of smoking and CHD
 - 74:6
- Stomach neoplasms
 - mortality rates
 - 67:158
 - mortality rates, by age and amount smoked
 - 67:157-158
 - mortality rates, by age and daily tobacco consumption
 - 67:158
 - mortality rates, by smoking classification
 - 67:157-158
 - mortality rates, effect of cessation of smoking on
 - 67:158
 - mortality ratios, by age and amount smoked
 - 67:157-158
 - mortality ratios, by smoking classification
 - 67:157
 - and smoking
 - 67:36
 - and tobacco use
 - 67:33
- Stomatitis nicotina
 - 64:275, 302
 - and pipe smoking
 - 64:271; 69:87
 - reverse smoking and
 - 72:6, 69, 70
 - symptoms of
 - 64:271
 - see also* Leukoplakia
- Stramonium
 - 64:354
- Stress
 - 64:373, 374
 - socioenvironmental, and coronary disease incidence
 - 67:56

- Stroke
 mortality rates, by age
 69:13
 mortality rates, by age and sex
 67:67
 mortality rates, by amount smoked
 69:13
 mortality rates, by sex
 69:13
 mortality ratios, by amount smoked
 69:13
 mortality ratios, by sex
 69:13
 and smoking
 67:27, 28; 72:24, 25
 see also Cerebrovascular diseases
- Strontium 90
 64:146
- Students, college
 smoking patterns in
 64:369
- Students, high school
 effect of smoking
 72:40, 41
 pulmonary function of smokers vs. non-smokers
 72:3
 respiratory symptoms
 72:40, 41
- Study populations
 representativeness of
 64:94
- Subcutaneous neoplasms
 64:143, 144
- Subglottis
 64:271
- Suburbs
 coronary diseases in
 64:322
- Sugar
 64:62
- Sulfonamides
 64:224
- Sulfur dioxide
 air pollution from
 64:295
 and cigarette smoke, effect on glands in laboratory animals
 73:49
 ciliastatic effect of
 64:268
 mucus alteration of
 64:268
 pollution levels in four U.S. locations
 75:65, 66
 toxicity of
 64:295
- Sulfuric acid
 carcinogen extraction by
 64:147
- Surfactant
 see Pulmonary surfactant
- Surgery
 complications following, in smokers vs. nonsmokers
 74:92
- Survey of Tobacco Smoking Patterns in the United States
 64:187
- Sweden
 acute effects of cigarette smoke on human pulmonary function
 71:168
 blood pressure differences in smokers vs. nonsmokers in
 71:104
 CHD mortality and morbidity in
 71:97
 COPD morbidity in smokers in
 71:203, 205
 coronary mortality rates in
 64:320
 effect of cigarette smoke on animals' ciliary function in
 71:221-224
 genetic studies of twins in, smoking effects on
 71:50, 99
 laryngeal neoplasms in relationship to tobacco use
 71:356
 lung neoplasm mortality rates in
 64:176
 relationship of tobacco use and lip neoplasms in
 71:361
 relationship of tobacco use and oral cavity neoplasms
 71:364
 retrospective studies of esophageal neoplasms, by tobacco use
 64:214; 71:378
 retrospective studies, of oral neoplasms, by type of smoking
 64:198, 200, 201
 retrospective study, of laryngeal neoplasms
 64:205, 206
 serum lipid differences in smokers vs. nonsmokers of
 71:99
 smoking and nicotine effects on human cardiovascular system
 71:115
 smoking and nicotine effects on human peripheral vascular system
 71:133
 tracheobronchial tree changes in smokers and nonsmokers in
 71:263
- Swimming
 effect of smoking
 73:242, 244
- Switzerland
 CHD morbidity and mortality in, smokers vs. nonsmokers
 71:95
 cigarette smoke effects on mice lung and kidney tissue in
 71:344
 cigarette smoke inhalation effects on mice respiratory tract
 71:351
 lung neoplasm incidence in cigar and pipe smokers of rural
 71:244

- lung neoplasm mortality rate in
 - 64:176
- lung neoplasms, methods of retrospective study of smoking in
 - 71:325
- serum lipid differences in smokers vs. nonsmokers of
 - 71:100
- Tachycardia
 - development in dogs induced by nicotine
 - 71:57
- Tars, cigarette
 - carcinogenic effect on animal oral cavities
 - 71:288
 - carcinogenicity
 - 67:34; 69:61; 71:11, 264, 265
 - carcinogenic properties on animal skin
 - 71:337-342; 73:210-214
 - as cause of bladder neoplasms, in rats
 - 74:58
 - content
 - 64:50; 67:34; 68:91
 - effect of instillation or implantation in animal tracheobronchial tree
 - 71:346-348
 - effect on RNA
 - 73:86
 - effect on tissue and organ cultures
 - 71:343-344
 - as harmful component of cigarette smoke
 - 72:142, 143
 - and nicotine content of cigarette smoke, and tumorigenicity
 - 67:15, 34
 - and nicotine content of cigarette smoke, as measurement of dosage
 - 67:15
 - N-nitrosamines in
 - 73:87, 88
 - reduction of
 - 69:61
 - retention in mouth
 - 69:62
 - role in experimental carcinogenesis
 - 73:80-84
 - role in respiratory tract carcinogenesis, in animals
 - 74:47
 - summary of previous findings on effects on smokers
 - 75:5
 - see also* Tars, tobacco
- Tars, tobacco
 - 64:50
 - alkaloid content of
 - 64:54
 - anticarcinogens in
 - 64:143, 144
 - application of, in carcinogenesis
 - 64:165
 - and bladder neoplasm carcinogenesis
 - 67:156
 - bladder neoplasms and
 - 64:219, 223
 - buccal retention of
 - 64:264
 - carcinogenicity
 - 64:33, 143, 146, 147, 165, 192; 67:128; 69:61; 72:65, 66
 - clearance of
 - 64:269
 - cocarcinogens in
 - 67:131
 - condensation temperature of
 - 64:50
 - definition
 - 72:143
 - dosage score as function of
 - 67:15
 - effect on respiratory symptoms and ventilatory capacity
 - 73:38
 - esophageal neoplasms and
 - 64:212, 213, 218
 - fatty acids in
 - 64:53
 - gastric neoplasms induced by
 - 64:228
 - and leukemia
 - 67:148
 - in little cigars, compared to cigarettes and cigars
 - 73:223-226, 228
 - and lymphosarcoma
 - 67:148
 - mouth neoplasm experimentally induced by
 - 67:147-148
 - nonvolatile fraction of
 - 64:50
 - pulmonary adenoma from
 - 64:165
 - retention of, in mouth
 - 64:264
 - and reticulosarcoma
 - 67:148
 - sarcoma induction in rats following instillation
 - 71:346
 - skin neoplasm induction by
 - 67:131; 71:238, 337-342; 73:210-214
 - sterol fraction of
 - 64:52
 - see also* Tars, cigarette
- Taste bud reflexes
 - 64:71
- Taylor's Manifest Anxiety Scale
 - 64:367
- TDE
 - 64:145
- Tea
 - 64:349
- Tecumseh Study
 - 64:284
 - incidence of CHD in cigarette smokers
 - 68:19
 - lung function differences in smokers and nonsmokers
 - 74:81

- Temperature effect
 - 64:50
- Ten-city mortality surveys
 - 64:135
- Tension
 - 64:353
- Teratogenesis
 - maternal smoking implications in
 - 71:407
 - in mice embryos, nicotine effects on
 - 71:411
- Terpenes
 - 64:51
- Terpenoids
 - 64:51, 52
 - as flavoring agents in cigarettes
 - 64:52
 - from pyrolysis of solanesol
 - 64:52
- Tetraethylammonium chloride
 - blockage of nicotine cardiac stimulation
 - by
 - 71:57
 - effect on nicotine pharmacology
 - 67:60
- Theobromine
 - 64:352
- Thiocyanate
 - 64:266
- Thorium
 - 64:145
- Thoron
 - 64:145
- Throat
 - effect of exposure to cigarette smoke, in
 - passive smokers
 - 75:99
 - effect of smoking
 - 64:275
- Thromboangiitis obliterans
 - allergic skin reactions in
 - 64:319
 - cessation of smoking, and remission
 - 71:74
 - cessation of smoking in
 - 64:326
 - definition
 - 71:73
 - tobacco allergy and
 - 72:111
 - treatment of
 - 64:326
- Thrombogenesis
 - effects of smoking
 - 68:32-43
- Thrombophlebitis
 - oral contraceptives and
 - 72:26
 - smoking and
 - 72:26
- Thrombosis
 - coronary
 - 64:321
 - effect of epinephrine on
 - 67:64
 - and emphysema
 - 67:111
 - plasma and
 - 69:27-28
 - smoking and
 - 67:26, 64, 65, 111; 69:27-28; 71:66, 130-132; 72:23; 73:19; 74:18, 19
- Thrombus formation
 - and smoking
 - 68:32-43; 69:27-28; 75:32
- Thumbsucking
 - 64:367, 368
- Tidal volume
 - acrolein effects on
 - 64:266, 267
- Tissue cultures
 - effect of cigarette smoke on
 - 69:62-63; 71:267, 343-345
- Tobacco
 - advertising, prohibition of
 - 64:8
 - allergic reaction to
 - 64:302
 - "angina"
 - 64:319
 - antigenic properties of
 - 64:319; 72:104
 - antigens, in smokers vs. nonsmokers
 - 72:107
 - anti-obesity effect of
 - 64:355
 - arsenic content of
 - 64:61, 62
 - arsenic spraying of
 - 64:61
 - beneficial effects of
 - 64:255, 355, 356
 - carcinogenicity of
 - 64:143
 - chemical composition of
 - 64:49, 50-60
 - cholesterol content
 - 72:24
 - controversy over
 - 64:5, 6, 7
 - curing methods, and incidence of respiratory infections in rats
 - 73:218, 219
 - denicotinized
 - 64:34, 349
 - effect on immune responses
 - 72:6, 107-109
 - flavoring in
 - 64:52, 62
 - flue-cured vs. air-cured, effect on respiratory system in animals
 - 73:217, 218
 - form used and relation to gingivitis
 - 69:86
 - history of
 - 64:5
 - humectants in
 - 64:62
 - irritants
 - 64:353
 - modification of taste of
 - 64:354
 - and mouth neoplasms
 - 67:145
 - in oral neoplasms
 - 64:198, 199, 200, 201

- and oral submucous fibrosis
 - 69:58
- pharmacologic, irritative, and allergic effects
 - 72:7, 109-111
- role in carcinogenesis
 - 69:62
- and stomach neoplasms
 - 67:33, 158
- see also* Tobacco additives; Tobacco extracts; Tobacco leaf components; Tobacco, pipe
- Tobacco Act of 1842
 - 64:62
- Tobacco additives
 - 64:62, 145
- flavorings as
 - 64:62
- humectants as
 - 64:62
- prohibition of
 - 64:62
- see also* Tobacco
- Tobacco alkaloids
 - see* Alkaloids, tobacco
- Tobacco amblyopia
 - see* Amblyopia, tobacco
- Tobacco chewing
 - 64:45, 211, 213, 349
- decrease of
 - 64:45, 211
- gingival neoplasms from
 - 64:202
- laryngeal neoplasms from
 - 64:212
- leukoplakia and
 - 73:75
- lip neoplasms from
 - 64:202; 71:361-363, 365-366
- oral neoplasms from
 - 64:233; 69:58; 71:361-363, 365-366; 72:69
- per capita consumption of chewing tobacco, U.S.
 - 64:45
- Tobacco consumption
 - 64:5, 26, 29, 30, 35, 36, 45, 46, 85, 86, 87, 89, 155, 187, 188
- bladder neoplasms, mortality rates by
 - 67:155
- bladder neoplasms, prevalence by
 - 64:223
- coronary diseases and
 - 64:106, 323
- coronary diseases, mortality rates by
 - 64:324
- cough and sputum prevalence by
 - 64:289
- epithelial cell changes by
 - 64:231
- errors of measurement of
 - 64:111
- esophageal neoplasm risk ratio by
 - 64:213, 217
- factors determining
 - 64:163
- forced expiratory volume by
 - 64:289
- gastric neoplasms mortality rate by
 - 64:228; 67:158
- laryngeal neoplasms risk ratios by
 - 64:209
- lung neoplasms mortality rates by
 - 64:137, 186
- lung neoplasms risk by
 - 64:37, 196, 232
- mortality rates by
 - 64:29, 105, 106, 111, 139, 180, 324
- mortality ratios by
 - 64:85, 86, 105, 106
- oral neoplasms gradients by
 - 64:202, 233
- per capita, U.S.
 - 64:45
- in pneumoconiosis
 - 64:291, 298
- relative risk ratios by
 - 64:183
- respiratory symptoms by
 - 64:289
- stress factors in
 - 64:32, 373, 374
- Tobacco extracts
 - 64:143, 144
- antigenic properties
 - 72:104, 105
- carcinogenesis from
 - 64:143, 144, 165
- effect on cell cultures
 - 73:85, 86
- effect on skin
 - 72:105-107
- irritants in
 - 72:104, 105
- thromboangiitis obliterans and
 - 72:111
- see also* Tobacco
- Tobacco habit
 - 64:349-354
- cure of
 - 64:354
- dependence on
 - 64:350
- nicotine in
 - 64:32, 349
- psychological drives in
 - 64:32, 350, 351
- see also* Smoking habit
- Tobacco Industry Research Committee
 - 64:6
- Tobacco Institute, Inc.
 - 64:8
- Tobacco leaf components
 - antigenic properties
 - 72:104, 105
 - polonium-210 in
 - 67:128
 - presence of potassium
 - 71:266
 - see also* Tobacco
- Tobacco, pipe
 - definition and processing
 - 73:176
 - decrease in consumption
 - 64:45

- per capita consumption, U.S.
64:45
- see also* Tobacco
- Tobacco workers
 - coronary diseases in
64:322
 - health studies in
64:182
 - laryngeal neoplasms in tobaccoists
64:205
- Tokyo-Yokohama asthma
64:276
- Toluene
64:55, 59
- Tongue
 - hamster, C-14 labeled particulate deposition in
71:281-282
- Tongue neoplasms
 - cigar smoking in
64:189, 202
 - pipe and cigar smoking in
64:202
 - pipe smoking in
64:188, 189
 - retrospective studies in, by type of smoking
64:201
 - risk gradients in
64:233
 - see also* Mouth neoplasms; Oral neoplasms
- Tooth extraction
 - effect of smoking on healing of socket
69:87
- Toxicity
 - birth rate reduction from
64:343
 - from nicotine
64:73
 - from sulfur dioxide
64:295
 - threshold levels in
64:295
- Trachea
 - changes in, in smokers
64:167-172
 - hamster, C-14 labeled particulate deposition in
71:281-282
 - histopathology of
64:167-172, 271
 - mucus secretion in
64:268
 - mucus velocity, effects of smoking, in dogs
75:78
- Tracheal neoplasms
 - experimentally induced by cigarette smoke
67:144
 - mortality rates, by amount smoked
67:147
 - mortality rates, by smoking classification
67:147
 - smoking and
73:71
- Tracheobronchial tree
 - clearance, effects of cigarette smoke in donkeys
75:78
 - epithelial changes in
64:167-172
 - function
64:35
 - histopathologic changes in
64:167-173, 270-274 *passim*
 - secondary infection in
64:272
- Traffic
 - effect on air pollution in Boston
74:82, 83
- Traffic accidents
64:39, 344, 345
- Tranquilizers
 - 64:100, 101, 354
 - nicotine as
64:350
- Transit workers
 - breathlessness in
64:286
 - chronic cough in
64:281
- Treadmill performance
 - cardiovascular parameters in smokers vs. nonsmokers
73:243-245
 - effect of vitamin C
73:245
 - oxygen intake in smokers vs. nonsmokers
73:245
- Tricaprylin
64:143
- Triglycerides
 - coronary disease relationship to
71:65; 73:8
 - smokers vs. nonsmokers
71:99-100, 102
- Trout
 - hepatoma induction in
64:145
- Tryptophan metabolism
 - alteration in urinary tract neoplasms by smoking
71:13
 - alterations by smoking
71:297
 - carcinogenicity in mice bladders
71:296
 - disorders, and bladder neoplasms
67:36, 106
 - disorders, effect of cessation of smoking on
67:156
 - effect of smoking on
67:36, 156
 - effect of smoking on, and bladder neoplasms
67:36
 - relation of excretion in smokers and nonsmokers
71:297

- Tryptophan metabolites
 - carcinogenic, and smoking
 - 67:36
 - carcinogenic, in urine, and bladder neoplasms
 - 67:36
 - excretion of, by smokers
 - 69:64
 - intermediate, and bladder neoplasms
 - 67:156
- Tuberculosis
 - 64:276, 302
 - alcohol consumption in
 - 64:277
 - cigarette consumption in
 - 64:277
 - in smokers vs. nonsmokers
 - 71:172, 226-228
 - smoking and
 - 72:41
- Tumors
 - see Neoplasms; and specific neoplasm terms
- Twenty-five State Study
 - expected deaths, in
 - 64:110
 - lung neoplasm mortality in
 - 64:118
 - mortality ratios in
 - 64:110, 118, 149
 - observed deaths in
 - 64:110
- Twins
 - air pollution exposure levels and respiratory symptoms
 - 75:67
 - air pollution vs. smoking in bronchitis development in
 - 67:109
 - air pollution vs. smoking in emphysema development using
 - 67:109
 - angina pectoris development in, smoking effects on
 - 71:50-51
 - blood cholesterol levels by smoking habit in
 - 67:55
 - constitutional factors in bronchitis development in
 - 67:109
 - constitutional factors in emphysema development in
 - 67:109
 - coronary disease incidence rates in, with discordant smoking habits
 - 67:103
 - cough incidence rates, smokers vs. nonsmokers by age and sex in
 - 67:102
 - dizygotic, bronchitis morbidity prevalence rates for, with discordant smoking habits
 - 67:103
 - dizygotic, chronic cough in, with discordant smoking habits
 - 67:103
- genetic and environmental factors in angina pectoris in
 - 69:25
- genetic studies of smoking effects on
 - 71:49-52
- monozygotic, angina pectoris incidence rates in, by smoking habit
 - 67:59
- monozygotic, bronchitis morbidity prevalence rates for, with discordant smoking habits
 - 67:113
- monozygotic, chronic cough in, with discordant smoking habits
 - 67:103, 113
- monozygotic, respiratory symptoms in, with discordant smoking habits
 - 67:103, 113
- morbidity rates by smoking habit in
 - 67:103
- mortality from CHD, in smokers vs. nonsmokers
 - 75:14, 15
- neoplasm incidence in
 - 64:190
- predisposition to smoking in
 - 64:326
- role of heredity factors in respiratory diseases in
 - 67:102
- role of respiratory tract diseases
 - 67:20
- smoking and coronary heart disease in
 - 72:18
- smoking effects on mortality and morbidity in
 - 71:51
- smoking habits of
 - 64:190
- Ultraviolet rays
 - absorption determination of
 - 64:51
 - neoplasm induction by
 - 64:144
- Underachievement
 - 64:372, 373
- Unemployed
 - smoking in,
 - 64:363
- United Kingdom
 - bladder neoplasms in, methods in retrospective studies of smoking and
 - 71:382-384
 - blood pressure differences in smokers vs. nonsmokers in
 - 71:103, 104
 - British Perinatal Mortality Survey
 - 71:390, 395, 404, 415
 - cigarette smoke effects on animal ciliary function in
 - 71:221
 - cigarette smoke effects on human fetal lung and mice trachea
 - 71:344

cigarette smoke effects on human pulmonary function
71:168, 169

cigarette smoke effects on mice respiratory tract
71:352

cigarette smoke implantation effects on rat tracheobronchial tree in
71:346-347

comparison of abortions, stillbirths and neonatal deaths in smoking and non-smoking mothers
71:406

COPD morbidity in smokers in
71:195-197, 203, 204

human experimental data on smoking and pregnancy in
71:408

kidney and bladder neoplasms in smokers in
71:294

lung neoplasms mortality in males in England and Wales
71:240

maternal smoking and infant weight in
71:397, 399

methods of retrospective study of lung neoplasms and smoking in
71:324, 326

methods used in smoking study and human pregnancy
71:391, 394-395

mortality from cerebrovascular disease related to smoking in
71:68

mortality rates from COPD in, lack of increase
71:140

mortality ratios from esophageal neoplasms in
71:290

mortality ratios from laryngeal neoplasms in
71:278

mortality ratios from peptic ulcer in smokers and nonsmokers in
71:424

occupational exposure and smoking relationships to COPD in
71:218-219

peptic ulcer in, methods and results of retrospective and cross section studies of smoking and
71:425-428

physicians in, decline in cigarette smoking rates
71:48

physicians in, mortality from lung neoplasms in smokers and nonsmokers
71:241

pulmonary function in, cigarette smoke effects on
71:168

relationship of lung neoplasms to smoking, air pollution, and residence in
71:253-254

relationship of smoking and tuberculosis in
71:226

serum lipid differences in smokers vs. nonsmokers in
71:101, 102

smoking and nicotine effects on animal cardiovascular function in
71:107

smoking and nicotine effects on human blood lipids in
71:126

smoking and nicotine effects on human cardiovascular system in
71:115

smoking relationships to thrombosis in
71:131

United States

acute effect of cigarette smoke on human pulmonary function in
71:166-167, 169

arteriosclerosis mortality in
64:321

atherosclerosis autopsy studies in
71:53-55

bladder neoplasms in, methods and results in retrospective studies of smoking and
71:381-384

blood pressure differences in smokers vs. nonsmokers in
71:103-104

Bureau of the Census
64:177

CHD mortality and morbidity in smokers vs. nonsmokers in
71:30-35, 37, 93-94

chewing tobacco consumption, decrease in
64:45

chronic bronchitis studies in
64:271

cigarette consumption increase in
64:26, 45, 46, 185

cigarette smoke effects on animal ciliary function in
71:221-224

cigarette smoke effects on animal tissues in
71:343-345

cigarette smoke effects on pulmonary surfactants and surface tension
71:172, 225

cigarette smoke implantation effects on animal tracheobronchial tree
71:346-348

cigarette smoke inhalation effects on animal respiratory tracts
71:349-350, 352, 354

comparison of abortions, stillbirth, and neonatal death in smoking and non-smoking mothers
71:405-406

COPD development in
71:10

COPD morbidity in smokers
71:195, 196, 198-200, 201-202, 205

- Department of Agriculture
64:15
- Department of Commerce
64:15
- esophageal neoplasms in, retrospective studies of tobacco use
71:378
- esophageal neoplasms mortality in, in 1967
71:289
- Food and Drug Administration
64:8, 13, 15
- human experimental data on smoking and pregnancy in
71:391-395, 408-410
- human pulmonary function following cessation of smoking in
71:149
- inhalation practices in, in smokers
64:177
- kidney and bladder neoplasms in smokers in
71:293-295
- laryngeal neoplasms incidence in 1967
71:277
- laryngeal neoplasms in, relationships to tobacco use
71:278-279, 354-355
- lung neoplasms mortality rates
64:176
- lung neoplasms mortality rates in, smokers and nonsmokers in
71:240-243
- maternal smoking and infant weight
71:397-399
- methods of retrospective study of lung neoplasms and smoking in,
71:323-328
- mortality from aortic aneurysm related to smoking in
71:71
- mortality from cerebrovascular disease related to smoking
71:68-70
- mortality rates for bladder neoplasms in 1967
71:293
- mortality rates for COPD
71:139-140
- mortality rates for kidney neoplasms in 1967
71:296
- mortality rates for lung neoplasms expected in 1970
71:237, 239
- mortality rates for lung neoplasms in 1939 vs. 1967
71:239
- mortality ratios for COPD
71:142-145
- mortality ratios for esophageal neoplasms in
71:290-294
- mortality ratios for laryngeal neoplasms
71:278-279
- mortality ratios for pancreatic neoplasms in smokers and nonsmokers in
71:298
- mortality ratios for peptic ulcer in smokers and nonsmokers in
71:424
- neoplasm mortality increase in
64:229
- nonsmokers in, by age and sex
64:178
- occupational exposure and smoking relationships to COPD in
71:218-219
- Office of Science and Technology
64:8
- oral neoplasms incidence in, estimated for 1970
71:284
- peptic ulcer in, methods and results for retrospective and cross section studies of smoking and
71:425, 426-428
- peptic ulcer mortality in 1967 in
71:423
- polonium-210 levels in lungs of smokers in
71:335-336
- Public Health Service
64:6, 13, 127, 343
- relationship of human pulmonary histology and smoking in
71:155-157
- relationship of lung neoplasms to smoking, air pollution, and residence in
71:253-254
- relationship of smoking to infectious respiratory diseases in
71:227-229
- relationship of tobacco use and lip neoplasms
71:361-365, 367
- relationship of tobacco use and neoplasms of oral cavity
71:361-365, 367
- retrospective studies in, neoplasms
64:150-165, 197-202, 205-209
- serum lipid differences in smokers vs. nonsmokers in
71:98, 100, 101
- smokers in, by age
64:177
- smoking and nicotine effects on animal cardiovascular function in*
71:107-112
- smoking and nicotine effects on human blood lipids*
71:123-126
- smoking and nicotine effects on human cardiovascular system*
71:113-114, 116, 117-119
- smoking and nicotine effects on human catecholamine levels*
71:119
- smoking and nicotine effects on human peripheral vascular system*
71:133-134
- smoking relationship to thrombosis in*
71:130, 131
- surveys of cigarette smoking in*
71:6

- tracheobronchial tree changes in smokers and nonsmokers in
71:259-263
- white males in, mortality rates in
64:95
- white population in, mortality ratios in
64:132
- United States veterans
64:109, 174
- chronic cough in
64:281, 282, 285
- expected deaths in
64:109
- mortality rates in
64:88, 293
- mortality ratios in
64:109, 149, 174
- nonresponse rate in
64:113
- observed deaths in
64:109
- respiratory performance in
64:297
- smoker mortality rates in
64:115
- University of Minnesota Hospital
64:140
- Unsaturated fats
64:322
- Unsaturated fatty acids
64:53
- Uranium miners
lung neoplasms in
64:193, 67:143; 71:256
- Urban areas
contribution to lung neoplasm mortality
71:11
- coronary disease incidence in
64:322
- lung neoplasm rates in
64:186, 194, 195; 71:276
- relationship of lung neoplasms, smoking, air pollution to
71:252-255
- smoking prevalence in
64:99, 101, 364
- Urbanization
64:186, 232
- Urban populations
lung neoplasms in, suspected etiology of increased
71:276
- Urban vs. rural populations
bladder neoplasm prevalence
64:225
- mortality rates
67:11
- smoking and
67:97
- Urethan
neoplasm promotion by
64:142
- neoplasms from
64:143, 144
- pulmonary adenomas from
64:144
- Urinary tract diseases
see Urogenital diseases
- Urinary tract neoplasms
see Urogenital neoplasms
- Urogenital diseases
64:224
- Urogenital neoplasms
cigarette smoke condensate as cause, in animals
74:58
- excretion of tryptophan in smokers vs. nonsmokers with
74:58
- incidence in males and females by age
68:104
- incidence in smokers vs. nonsmokers
74:58
- mortality and smoking factors in bladder neoplasms
68:104, 105
- mortality rates, by age
67:154
- mortality rates, by amount smoked
67:154
- mortality rates, by smoking classification
67:154
- mortality ratios, by age
67:154
- mortality ratios, by amount smoked
67:154
- mortality ratios, by smoking classification
67:154
- smoking and
69:60, 64; 75:50
- summary of previous findings on relationship to smoking
68:89, 90; 74:57
- see also Bladder neoplasms; Kidney neoplasms
- Uterus
cigarette smoking effects on, in pregnancy
71:408
- Vanillin
64:62
- Vascular diseases, occlusive
64:319
- smoking and
73:21
- Vascular diseases, peripheral
carboxyhemoglobin levels and
72:26
- epidemiologic studies
74:14-16
- experimental studies
74:16
- nicotine and
72:25
- smokers vs. nonsmokers
72:26
- smoking as a risk factor
72:2, 25, 26, 56; 73:19-23; 74:14-16
- Vascular reconstruction
effect of smoking
73:22, 23

- Vascular resistance
 - effect of cigarette smoke on
 - 67:61
 - effect of histamine on
 - 67:61
 - effect of nicotine on
 - 67:60
 - effect of smoking on
 - 67:60
- Vascular system
 - peripheral, smoking and nicotine effect on
 - 71:9, 72-73, 75, 133-134
- Vasoconstriction
 - fetal weight reduction by
 - 64:343
 - nicotine induction of
 - 64:318
 - pulmonary, effects of cigarette smoking
 - 68:75, 76
- Vegetable fibers
 - 64:59
- Venezuela
 - maternal smoking and infant weight in
 - 71:450
 - methods used in smoking study and human pregnancy
 - 71:445
- Ventilation
 - effects on constituents of tobacco smoke
 - 75:90-95
- Ventilatory function
 - 64:35, 292, 300, 302
 - effect of exercise and smoking
 - 73:244, 245
- Ventricular fibrillation
 - 64:321
 - death from, nicotine effects on
 - 71:36
 - effect of cigarette smoke in dogs
 - 73:13, 14
- Ventricular hypertrophy
 - as a risk factor in CHD
 - 73:8
- Ventricular premature beats
 - effect of cigarette smoking
 - 75:20
- Veterans
 - see* Canadian veterans study; United States veterans
- Viruses
 - as etiologic agent in cancer
 - 64:166, 230
 - influenza, cigarette smoke effects on resistance of mice with
 - 71:173
 - influenza, nitrogen oxide effects on squirrel monkey resistance to
 - 71:173
 - neoplasm induction by
 - 64:142
- Vision
 - carboxyhemoglobin effect on
 - 64:344
 - effect of carbon monoxide
 - 72:126
- effect of smoking on
 - 67:183
- Vitamin B complex
 - deficiency, and tobacco amblyopia
 - 67:40, 183
- Vitamin B 12
 - deficiency,
 - 64:212
 - deficiency, potentiation of cyanide in tobacco amblyopia
 - 67:40, 183
 - in pregnant smokers vs. nonsmokers
 - 73:119
- Vitamin C
 - effect on treadmill performance in smokers vs. nonsmokers
 - 73:245
 - in milk of smoking mothers
 - 73:141
 - in pregnant smokers vs. nonsmokers
 - 73:119
- Vitamin D
 - and nicotine, effect on hypercholesterolemic rabbits
 - 69:27
- Vocal cords
 - effect of smoking on thickness
 - 69:59-60
 - hyperkeratosis in
 - 64:271
 - see also* Larynx
- Waiters
 - esophageal neoplasms in
 - 64:134
 - oral neoplasms in
 - 64:134
- Washington University study
 - 64:174
- Water
 - hardness, and smoking as risk factors in CHD
 - 73:9, 10
 - soluble fraction of cigarettes, suppression of immunoglobulin response
 - 75:77
- Welsh miners
 - 64:293, 294
- Western Collaborative Group Study
 - CHD risk factors, in smokers vs. nonsmokers
 - 68:25, 26
 - incidence of myocardial infarction in younger male smokers
 - 68:21
- White House Conference on Narcotics and Drug Abuse
 - 64:355
- White Pekin duck
 - nature of phagocytized clearance products in
 - 64:269
- Whites
 - cancer mortality in
 - 64:135

- esophageal neoplasms in
 - 64:218
- laryngeal neoplasm prevalence in
 - 64:209
- mortality rates
 - 64:133
- mortality ratios by sex
 - 64:133
- smoking patterns in
 - 64:363, 364
- Wire implantation
 - 64:166
- Withdrawal
 - clinics
 - 67:191
 - methods
 - 64:354
 - symptoms
 - 64:352, 354
 - see also* Cessation of smoking
- Women
 - autopsy studies, in smokers vs. nonsmokers with emphysema, fibrosis, or thickening of arterioles or arteries
 - 75:75
 - blood pressure and smoking habits during pregnancy
 - 69:77-78
 - CHD incidence in
 - 74:9, 10
 - exposure to chemicals, fumes, sprays and dusts, in smokers vs. nonsmokers
 - 75:69, 70
 - hypertension, in cigarette smokers with CHD
 - 68:22
 - incidence of lung neoplasms
 - 68:97; 74:39, 40; 75:43
 - incidence of lung neoplasms and smoking
 - 69:4, 57
 - increase in mortality from lung neoplasms
 - 75:47
 - mortality from lung neoplasms
 - 68:97
 - mortality, in smokers vs. nonsmokers
 - 68:6, 8, 9
 - mortality rates from lung neoplasms and asbestos exposure
 - 74:42, 43
 - mortality rates from lung neoplasms, statistical sex ratio
 - 74:40, 45
 - mortality rates, in smokers vs. nonsmokers
 - 74:9, 10
 - myocardial infarction in pre- vs. post-menopausal
 - 74:10
 - myocardial infarction, in Swedish smokers vs. nonsmokers
 - 75:14
 - secular trends of lung neoplasm development in
 - 74:40
 - sudden death rates in
 - 74:9, 10
 - summary of previous findings on effects of smoking
 - 75:5-7
 - trends in neoplasm incidence rates for selected sites in
 - 74:41, 42
- Working classes
 - 64:362
- Work-loss days
 - definition
 - 67:19
 - and smoking
 - 67:20-21
- World Health Organization
 - 64:350, 354
 - classification of lung neoplasms
 - 64:173, 174
- Xenon
 - radioactive, regional pulmonary function using
 - 71:147
 - washout technique for detection of lung neoplasms
 - 74:43, 44